ARCA biopharma, Inc.
ABIO
ABIO: ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
moreShow ABIO Financials
Recent trades by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ABIO's directors and management
Government lobbying spending instances
-
$20,000 Jul 20, 2011 Issue: None
-
$50,000 Apr 19, 2011 Issue: Defense Health Issues Veterans
-
$50,000 Jan 20, 2011 Issue: Veterans Defense Health Issues
-
$50,000 Oct 20, 2010 Issue: Health Issues Defense Veterans
-
$50,000 Jul 20, 2010 Issue: Defense Health Issues Veterans
-
$50,000 Apr 20, 2010 Issue: Defense Health Issues Veterans
-
$30,000 Jan 20, 2010 Issue: Veterans Health Issues Defense
New patents grants
Federal grants, loans, and purchases
Followers on company's Twitter account
Number of mentions of ABIO in WallStreetBets Daily Discussion
Recent insights relating to ABIO
Recent picks made for ABIO on CNBC
ETFs with the largest estimated holdings in ABIO
Flights by private jets registered to ABIO